A recent study showed that EV-ligand-dependent corepressor mRNA therapy in combination with PD-L1 inhibitor overcame resistance and metastasis in preclinical breast cancer models (Pérez-Núñez et al., 2022). This evidence concerns the gene CD274 and breast cancer.